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The effect of acute pre-surgery 
dexamethasone treatment on the inflam-
matory immune and endocrine responses
to orthopaedic surgery was investigated.
Whole blood samples were obtained before
and 5 days after surgery for immune
analysis, and serum was obtained before
and 6 h, 3 days and 5 days after surgery for
endocrine assessment. Dexamethasone did
not affect the post-surgery granulocyte
response, but inhibited the increase in
monocyte count (an average increase of
38.5% was seen in the control group). Peak
C-reactive protein concentration (3 days
after surgery) was 51.4% lower in the
dexamethasone group than in the 
control group. Dexamethasone had a
major effect on cortisol concentrations 
and the cortisol:testosterone and cortisol:
dehydroepiandrosterone ratios, but no
effect on anabolic hormone concen-
trations. In conclusion, acute pre-surgery
dexamethasone treatment may have
beneficial effects in the post-surgery
period, by limiting the extent of systemic
inflammation and the cortisol response.
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Introduction
Both myofibrillar and whole-body protein
catabolism have been shown to increase
post-operatively in surgically stressed
patients.1 This increased protein catabolism
has been ascribed to the mobilization of
skeletal muscle proteins for redistribution to
support vital organs, improve resistance to
infection and aid wound healing.2 The
hormone ultimately responsible for this post-
injury mobilization of protein is the stress
hormone cortisol.3 Although an elevation in
circulating cortisol is necessary in the post-
operative period, the subsequent catabolic
process requires a counteracting process 
of muscle growth to prevent severe decreases
in muscular strength and prolonged
convalescence.
However, even at rest, the circulating
concentrations of some of these vital
anabolic hormones, e.g. dehydro-
epiandrosterone and growth hormone, 
have been shown to decline with age, 
while that of the catabolic hormone cortisol
has been reported to be increased in older
subjects.4 – 6 This effect of ageing on the
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balance between the anabolic and catabolic
arms of the endocrine system may have
negative implications for the recovery of
elderly patients after surgical procedures.
Dexamethasone is a synthetic cortisol
antagonist routinely used to probe central
glucocorticoid sensitivity in the diagnosis
and treatment of depression.7 Dexa-
methasone administration in rats was
reported to inhibit the glucocorticoid
response by blocking peripheral
glucocorticoid receptors (i.e. in the pituitary
and spleen), while having no effect 
on glucocorticoid receptor binding in the
brain (hypothalamus, hippocampus and
cortex).8 In another rat study, low-dose
dexamethasone administration (0 – 50 µg/kg)
was shown to result in a dose-dependent
reduction in stress-induced corticosterone
concentration in restrained rats, a higher
dose of dexamethasone resulting in a greater
reduction.9 Dexamethasone may therefore
be a useful tool to prevent an ‘overshoot’ of
the catabolic response to elective surgery,
especially in the elderly. Other side-effects
experienced post-operatively include pain
and nausea, on which the effects of a 
single dose of dexamethasone treatment
have also been investigated. The single 
dose of dexamethasone administered
intravenously during surgery tended to
reduce pain in the first few days after surgery
in adult patients who had undergone
tonsillectomy.10 A single 8 mg dose of
dexamethasone was unsuccessful as an
antiemetic.11 In contrast, in a larger study 
of 300 patients, 4 mg dexamethasone
administered after the induction of
anaesthesia, with a second dose on the
morning after surgery, significantly reduced
nausea and vomiting and improved
appetite.12 This suggests another possible
beneficial effect of dexamethasone
treatment in the prevention of catabolic
processes. In patients undergoing
rhinoplasty, a single dose of dexamethasone
administered either before or after 
surgery reduced both upper and lower 
eyelid oedema for the first 2 days after
surgery, suggesting a possible anti-
inflammatory effect.13
Unfortunately, the effects of altered
glucocorticoid action on anabolic hormones
or the immune system were not assessed in
these studies, so it is unclear what effect
dexamethasone administration may have
on the balance between pro- and anti-
inflammatory responses. A recent review14
summarized the net effects of stress and
ageing on immunity, and proposed a 
‘double-hit’ model for stress and ageing,
whereby the age-related increase in the
cortisol:dehydroepiandrosterone sulphate
(DHEAS) ratio synergizes with stress-induced
elevated cortisol to reduce immunity in the
elderly significantly. Limiting the cortisol
response to surgical stress therefore seems 
to be a form of management worth
investigating. On the other hand, for wound
healing to occur, inflammation (i.e. 
pro-inflammatory cells and cell debris) needs
to be cleared from the site of injury.
Therefore, despite its negative effects on
immunity in the elderly and protein meta-
bolism after surgery, cortisol is required in
the post-surgery period for its anti-
inflammatory action. It is therefore vital to
ensure that the immune cell count and
distribution are not altered too much as a
result of dexamethasone administration.
The aims of this study were (i) to
investigate whether administration of a stat
dose of dexamethasone prior to surgery may
limit the sharp increase in circulating
cortisol reported after surgery; and (ii) to
determine the effects of such a treatment on
the anabolic endocrine and the immune
responses to surgery.
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Patients and methods
PATIENTS
Male patients undergoing unilateral total
knee replacement surgery were recruited for
this study through their orthopaedic
surgeon. Subjects undergoing the procedure
as a result of malignancy or chronic disease,
as well as subjects with a history of endocrine
pathology, were excluded from the study. All
subjects were informed about the study and
gave their written consent prior to
participating in the study. Ethical approval
for the study was granted by the Stellenbosch
University Subcommittee C and the Medi-
Clinic ethics boards.
INTERVENTION
All subjects were subjected to similar protocols
for epidural anaesthesia and surgical
procedures. All knee replacements were
carried out by the same orthopaedic surgeon.
However, 50% of patients also received a
single dose of 16 mg dexamethasone
epidurally directly after placement of the
epidural catheter. (This dosage was chosen in
accordance with that commonly used in
elective surgery, to limit undesirable side-
effects experienced post-operatively, such as
nausea, vomiting, pain and swelling.)
SAMPLE COLLECTION AND
ANALYSIS
Whole blood samples were collected by
venepuncture into SST Vacutainer tubes (BD
Systems, Plymouth, UK) before surgery and
again 6 h, 3 days and 5 days after surgery,
for the determination of the serum
concentrations of cortisol, testosterone,
DHEAS, growth hormone and C-reactive
protein (CRP). In addition, blood samples 
in ethylenediaminetetraacetic acid were
collected before surgery and again 5 days
after surgery, for the determination of total
and differential white blood cell (WBC)
counts. With the exception of the 6-h post-
surgery samples, all samples were drawn in
a fasted, rested state at 08.00, by a registered
phlebotomist. Patients consumed only fluids
for the first 6 h after surgery. Samples were
then transported to the on-site pathology
laboratory, where they were processed
immediately for all parameters (total and
differential WBC, CRP, cortisol, testosterone,
growth hormone, DHEAS) by automated
analytical procedures (STKS & Access B
module 81600, Beckman/Coulter, Fullerton,
California, USA; Immulite I, Diagnostic
Products Corporation, Los Angeles,
California, USA; Advia Centaur, Bayer
Diagnostics, Leverkusen, Germany).
STATISTICAL ANALYSIS
All results are represented as mean ± SD. The
effects of time and/or treatment alone, as
well as the interaction effect of both time and
treatment, on the selected immune and
endocrine parameters were determined by
factorial analysis of variance (ANOVA) and
Bonferroni post hoc tests. P-values < 0.05
were considered to be statistically significant.
Results
Twelve male patients, aged 65 ± 9 years,
undergoing unilateral total knee replacement
surgery were recruited (n = 6 in the
dexamethasone group and n = 6 in the control
group). ANOVA indicated an effect of time 
(P < 0.005) on total and differential WBC
counts, but no effect of dexamethasone
treatment on these parameters. Bonferroni
post hoc testing indicated similar significant
increases in both the control and
dexamethasone groups for both total WBC
and neutrophil counts 5 days after surgery
(P < 0.05); the monocyte count was
significantly increased from pre-surgery values
at the same time-point, but only in the control
group (P < 0.05) (Table 1). A main effect of
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time was reported for CRP concentration 
(P < 0.00001), as well as a main effect of
treatment, indicating that the elevations in
CRP over time differed in the dexamethasone
group (P < 0.001). Specifically, the interaction
effect between time and treatment (P < 0.005)
and the Bonferroni post hoc analysis illustrated
a lower peak CRP concentration in the
dexamethasone group 3 days after surgery
(Fig. 1).
Similarly, factorial ANOVA indicated main
effects of time (P < 0.05) and treatment 
(P < 0.0005) on serum cortisol concentration.
However, the Bonferroni post hoc analysis
indicated that the significantly lower cortisol
concentration in the dexamethasone group
was evident at an earlier time-point than 
CRP, namely 6 h after surgery (P < 0.01) 
(Fig. 2A). The anabolic hormones analysed did
not follow the same responses as those seen for
cortisol and CRP. Although testosterone
concentration was affected by time 
(P < 0.0005), it was not affected by treatment
(Fig. 2B). Serum concentrations of DHEAS and
growth hormone did not seem to be affected
by either treatment or time (Table 2). Taking
into account that the net catabolic status may
be influenced by the ratio between catabolic
and anabolic variables, ratios between cortisol
and testosterone and between cortisol and
DHEAS were also calculated. First, it was
noticeable that the large variability in
response between subjects (large standard
deviations) for both cortisol and testosterone
was greatly diminished by assessing the 
ratio between these two parameters in the 
early response to the surgical intervention 
(Figs 2A – 2C). The variability between sub-
jects was evident again 5 days after surgery.
Also, a dramatic effect of time was no longer
evident. Rather, ANOVA indicated main
effects of treatment on cortisol:testosterone 
(P < 0.05; Fig. 2C) and cortisol:DHEAS 
(P < 0.01; Table 2) ratios, with values lower in
the dexamethasone group compared with
the control group for both variables.
TABLE 1: 
Changes in total and differential white blood cell (WBC) counts over time after unilateral
knee replacement surgery in 12 male subjects with or without a pre-surgery single dose of
16 mg dexamethasone administered epidurally (n = 6 per group)
5 days after 
Parameter Normal range Group Before surgery surgery
WBC (× 109/l) 4.00 – 11.00 Control 7.18 ± 0.81 8.90 ± 2.38a
Dexamethasone 7.22 ± 1.87 9.22 ± 3.20a
Neutrophils (× 109/l) 2.50 – 7.50 Control 4.23 ± 0.74 6.08 ± 1.84a
Dexamethasone 4.27 ± 1.11 6.22 ± 2.11a
Lymphocytes (× 109/l) 1.50 – 3.50 Control 2.02 ± 0.53 1.60 ± 0.54
Dexamethasone 1.99 ± 0.62 1.93 ± 0.85
Monocytes (× 109/l) 0.20 – 0.80 Control 0.65 ± 0.23 0.90 ± 0.33a
Dexamethasone 0.70 ± 0.23 0.71 ± 0.33
Values are mean ± SD.
Groups were compared using main effects analysis of variance with Bonferroni post hoc tests.
aP < 0.05 compared with the before-surgery value in the same group.
No inter-group differences were evident before or after surgery.
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TABLE 2: 
Changes in hormone concentrations and ratios after unilateral knee replacement surgery
in 12 male subjects with or without a pre-surgery single dose of 16 mg dexamethasone
administered epidurally (n = 6 per group)
Before 6 h after 3 days after 5 days after 
Parameter Group surgery surgery surgery surgery
DHEAS (µmol/l) Control 2.07 ± 0.83 1.65 ± 0.61 1.55 ± 0.49 2.20 ± 2.03
Dexamethasone 2.50 ± 1.17 1.63 ± 0.87 1.20 ± 0.56 1.35 ± 0.66
Growth hormone Control 3.18 ± 3.79 2.34 ± 1.48 2.15 ± 2.70 3.38 ± 3.61
(µIU/ml) Dexamethasone 2.24 ± 4.83 3.46 ± 1.77 1.79 ± 2.03 1.55 ± 1.25
Cortisol:DHEAS Control 0.20 ± 0.12 0.49 ± 0.35 0.21 ± 0.07 0.41 ± 0.29
ratio Dexamethasone 0.11 ± 0.07 0.08 ± 0.10a 0.12 ± 0.08 0.37 ± 0.21
Values are means ± SD.
Analysis of variance shows the effect of time on cortisol:dehydroepiandrosterone sulphate (DHEAS) 
ratio (P < 0.01).
Bonferroni post hoc analysis: aP < 0.05 compared with the control group.
FIGURE 1: Serum C-reactive protein (CRP) concentrations before and after unilateral knee
replacement in 12 male subjects, with or without a pre-surgery single dose of 
16 mg dexamethasone administered epidurally (n = 6 per group). ***Value different from
all other values (P < 0.005); **value different from all values before surgery and 
6 h after surgery, and from control at the indicated number of days after surgery 
(P < 0.005); *value different from all values before surgery and 6 h after surgery, and from
control at the indicated number of days after surgery (P < 0.05). Values are mean ± SD
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FIGURE 2: Effect of unilateral knee replacement surgery in 12 patients, with or without a
pre-surgery single dose of 16 mg dexamethasone administered epidurally (n = 6
per group), on the circulating concentrations of cortisol and testosterone. (A) Cortisol. Ψ,
ANOVA, effect of treatment, values for the dexamethasone group are significantly lower
compared with the control group (P < 0.0005); *value significantly different from values
before surgery and at 6 h and 3 days after surgery in the dexamethasone group 
(P < 0.01); **value significantly different from values at 6 h and 3 days after surgery in the
dexamethasone group (P < 0.05). (B) Testosterone. (C) Cortisol:testosterone ratio. Ψ,
ANOVA, effect of treatment, values are lower in the dexamethasone group than in the
control group (P < 0.05). Values are mean ± SD
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Discussion
The main novel finding of this study was
that administration of a single moderate
dose of dexamethasone prior to orthopaedic
surgery prevented a post-surgery increase in
monocyte count. The data also illustrate the
following additional main effects: (i)
limitation of peak CRP concentrations 3 days
after surgery; and (ii) attenuation of the
acute post-surgery increase in circulating
cortisol without affecting serum levels of the
anabolic hormones assessed (testosterone,
DHEAS and growth hormone).
The stress of orthopaedic surgery results in
a systemic inflammatory response. This
inflammatory response is the result of
cumulative effects of, for example,
anaesthesia,15 autologous infusion of filtered
whole blood16 and mechanical stress and
tissue damage caused by the surgical
procedure itself. The finding of increased
total WBC and neutrophil counts in the post-
surgery period is therefore not unexpected.
In addition, these results indicate that
administration of a single moderate dose of
dexamethasone prior to surgery does not
affect this post-surgery granulocyte response.
However, dexamethasone did inhibit the
monocyte response that was seen in the
control group and this lasted up to 5 days
after surgery. This novel in vivo finding is
similar to the findings of an earlier study,
which reported monocytopenia within 
4 – 6 h after oral administration of a single
dose of 12 mg dexamethasone.17 Taken
together, these data suggest that the anti-
inflammatory effect of dexamethasone may
be limited to the mononuclear cell lines, the
granulocyte cell lines being unaffected.
The role of neutrophils after surgery is to
phagocytose any debris and damaged cell
matter that result from the surgical
procedure, and it is therefore important to
note that this positive role is not inhibited 
by dexamethasone treatment. Monocyte
infiltration is, in turn, necessary to clear
these neutrophils from the injury site, so that
healing may occur. There is more than one
possible explanation for the unchanged
monocyte count seen in the circulation in
the dexamethasone group. First, it may
indicate better infiltration of monocytes from
the circulation into damaged tissue.
However, since a study in rats illustrated no
effect of dexamethasone treatment on
monocyte (macrophage) infiltration into a
tumour, and even inhibition of microglia
and lymphocyte infiltration,18 this
explanation is unlikely. A second explanation
is that the unchanged circulating monocyte
count may be the result of a lack of
proliferation or a lack of mobilization of
monocytes. Whether or not dexamethasone
affects peripheral blood mononuclear cells (of
which monocytes form a part) has been
addressed in several other studies which have
recently been reviewed.19 The review assessed
both clinical studies in which patients were
treated with dexamethasone and in vitro
studies in which blood samples were
incubated with dexamethasone. The authors
concluded that dexamethasone treatment has
an inhibitory effect on the activation of
peripheral blood mononuclear cells.
Therefore, the inhibited monocyte response is
likely to be due to a dexamethasone-induced
reduction in cell proliferation.
Whether the lack of elevation in
monocyte count in the dexamethasone
group might lead to slower clearance of
inflammation remains to be investigated.
The fact that the CRP levels did not change
between 3 and 5 days after surgery in the
dexamethasone group could be interpreted
as indirect evidence of this delay. In
contrast, administration of dexamethasone
decreased the peak concentration of CRP
seen in circulation 3 days after surgery. This
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result implies that the peak inflammatory
response was attenuated. Although assessed
in circulation, this may be indicative of a
lower peak magnitude of inflammation at
the tissue level in response to the surgery in
the dexamethasone group than in the
control group.
A potentially beneficial effect of
dexamethasone, which is illustrated in this
study, is the limitation of the catabolic
process induced by cortisol. Although it is
known from rat studies that dexamethasone
suppresses cortisol secretion by inhibition of
the hypothalamo–pituitary–adrenal axis at
the level of the pituitary glucocorticoid
receptors,8,9 this study is the first in human
subjects to show a suppressed cortisol
response to knee replacement surgery 
after a single dose of dexamethasone.
Concentrations of the anabolic hormones
testosterone, DHEAS and growth hormone
were not affected by dexamethasone
treatment. This resulted in a net reduction in
the ratios of catabolic to anabolic hormones.
This suggests that dexamethasone blocks the
action of cortisol without affecting the
anabolic pathway. Therefore, this action of
dexamethasone may suggest a treatment for
the prevention of surgery-induced catabolic
states without the side-effects generally
associated with exogenous administration of
anabolic hormones.20,21
In conclusion, these results indicate a
beneficial effect of a single moderate dose of
dexamethasone, administered prior to
orthopaedic surgery, for the maintenance of
anabolic versus catabolic endocrine action.
Furthermore, the use of dexamethasone
seems to decrease the magnitude of
inflammation at the site of surgery. The
potential benefits of these effects may be
outweighed in part by slower clearance of
inflammation later, but this remains to be
investigated in more detail. Also, the possible
downstream effects on the maintenance of
skeletal muscle mass and recovery time after
surgery warrant further investigation.
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